143 results
8-K
EX-99.2
OPTN
OptiNose Inc
14 May 24
Optinose Reports First Quarter 2024 Financial Results
7:08am
to: the potential benefits of the recent FDA approval of XHANCE for the treatment of chronic rhinosinusitis without nasal polyps (also referred … to as chronic sinusitis); the benefit of XHANCE for treatment of chronic sinusitis; our commercial plans and expectations for XHANCE; the generation of XHANCE
8-K
EX-99.1
OPTN
OptiNose Inc
14 May 24
Optinose Reports First Quarter 2024 Financial Results
7:08am
population with chronic rhinosinusitis who do not have nasal polyps. Millions of people can potentially benefit from this landmark approval because … , despite being one of the most common diagnoses in adult outpatient medicine, there has never been an approved prescription treatment for Chronic
424B5
OPTN
OptiNose Inc
9 May 24
Prospectus supplement for primary offering
7:09am
Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal … polyps. Chronic rhinosinusitis is a serious nasal inflammatory disease that is treated using therapies, such as intranasal steroids (INS), which have
8-K
EX-99.1
OPTN
OptiNose Inc
9 May 24
Optinose Announces $55 Million Registered Direct Offering
7:04am
as a prescription treatment for chronic rhinosinusitis without nasal polyps is a strong foundation for pursuing future growth opportunities. We expect the post … financial footing, our team looks forward to helping millions of patients suffering from chronic sinusitis by making the first effective prescription
424B5
p6w6emxcu orn
9 May 24
Prospectus supplement for primary offering
7:03am
424B5
154otmghuhm1b
9 May 24
Prospectus supplement for primary offering
7:02am
8-K
EX-99.2
rhq6089zceixl3sjm9
25 Apr 24
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
7:41am
8-K
EX-99.1
vkk7q4nd usrp
25 Apr 24
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
7:41am
8-K
EX-99.1
jik prssswpf
15 Mar 24
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
3:36pm
8-K
ul80vwgn3f15oz26q3ga
15 Mar 24
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
3:36pm
8-K
EX-99.2
0artwvod5iuvh
7 Mar 24
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
8-K
EX-99.1
emw tqapi
7 Mar 24
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
8-K
tzrtrp
6 Dec 23
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
7:02am
8-K
EX-99.1
2ilffg6pq8ohq6ulf
6 Dec 23
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
7:02am
8-K
EX-99.1
wewes18
9 Nov 23
Optinose Reports Third Quarter 2023 Financial Results
7:02am
8-K
EX-99.2
11d3862p
9 Nov 23
Optinose Reports Third Quarter 2023 Financial Results
7:02am